Business Context and Reporting Period
This Form 6-K filing by Bionomics Limited (not Neuphoria Therapeutics Inc.) covers the month of January 2022, with a filing date of January 12, 2022. The registrant is a Foreign Private Issuer based in Australia. The report serves to furnish a corporate presentation delivered at the H.C. Wainwright BioConnect Conference on January 9, 2022, which was originally lodged with the Australian Securities Exchange (ASX).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document is a procedural filing intended to attach a conference presentation (Exhibit 99.1) and does not contain a financial statement or numerical data within the body of the report.
Material Changes
No material changes to financial performance or operations are detailed in this specific filing text. The document explicitly states that the attached presentation contains summary information and is not an admission of materiality for any information contained therein.
Guidance, Outlook, and Risks
The filing includes standard disclaimers regarding the attached presentation. Management undertakes no duty or obligation to update or revise the information contained in the report, though updates may be made via future SEC filings, press releases, or website updates. The text notes that the presentation should be considered in the context of more complete information in other SEC filings and public announcements.
Investor Verification Checklist
- Verify the correct registrant name is Bionomics Limited, as the input metadata incorrectly listed Neuphoria Therapeutics Inc.
- Review Exhibit 99.1 (the attached presentation) for specific operational updates, as the filing text itself contains no data.
- Consult the company's most recent Form 20-F or quarterly reports for actual financial metrics, as this 6-K does not report numbers.
- Confirm the date of the H.C. Wainwright BioConnect Conference presentation (January 9, 2022) to ensure context alignment.